Organizers & Speakers

Professor Strauss is a highly accomplished pediatrician and neonatology specialist, with a wealth of experience in her field. She received her medical degree from the Rappaport Institute of Technology in Haifa, and holds an MPH from the Harvard School of Public Health. In addition, she holds a Professor degree from Tel Aviv University.

For over a decade, Professor Strauss has served as the Director of the Neonatology Department at Sheba Medical Center. In this role, she has published numerous articles and reviews in her field, and has been a member of numerous committees in her area of expertise.

In the last two years, Professor Strauss has taken on the responsibility of developing one of the first academic and clinical research centers for longevity in a public hospital. The Longevity Academic Center, which Professor Strauss leads, aims to improve our understanding of aging and longevity, and to identify opportunities for improving the quality of life and function in older age. The center focuses on the study of health and wellness from young adulthood through the centenarian age group (45-100 years old), including cutting edge diagnostic techniques, the analysis and monitoring of health biomarkers, and the study of multidisciplinary interventions.

Internal medicine and oncology University Hospital Renji of Jiaotong University,
Shanghai
Sheba Longevity Center, Tel Hashomer
Specialist in Internal Medicine, Artificial Intelligence (AI) and digital health, with
extensive experience in scientific research and clinical practice at the following
well known and highly reputable institutions. Research focus is oncology and
longevity medicine, Artificial Intelligence (AI) and digital health, precision
medicine, biogerontology, and geronto-oncology. EB published over 100 peer-
reviewed papers, is a frequent speaker at scientific and medical conferences in
Asia and Europe. Long term member of various medical societies, e.g. European
Federation of Internal Medicine, World Academy of Medical Sciences, Swiss
Society of Internal Medicine etc.
EB spent a decade practicing medicine, lecturing at medical schools and
performing clinical and translational research in New York, Shanghai and Basel,
with extensive experience in scientific research and clinical practice at the

following well-known and highly reputable institutions: University Hospital of
Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital
and Shanghai East Hospital. EB sits on several scientific and advisory boards of
biotech and longevity hubs. Currently also affiliated with the Centre of Healthy
Aging, Universität Zürich, and prev. senior attending physician of internal
medicine at the University Hospital Basel.
Swiss board certified as internal medicine specialist (FMH), trained in Europe,
USA and China (Harvard Medical School affiliated hospitals (Mass General
Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC;
Tongji University hospitals, Shanghai and University Hospitals of Zurich and
Basel (Switzerland).

Abigail leads the Research and Development unit at the Sheba Longevity Center. Abigail started her academic career with a BS in Molecular Biology, followed by another BS in Nutritional Science, as well as an internship as a clinical dietitian at several rehabilitation hospitals. Her master’s and Ph.D. degrees were completed at the School of Public Health in the Epidemiology and Preventive Medicine Department at Tel-Aviv University. Her main areas of research are aging epidemiology trajectories, predictors of frailty, cognitive decline, and successful aging among community-dwelling oldest-old adults. She specializes in designing large population cohorts and developing computerized prognostic models for the early detection of frailty and predicting adverse outcomes.

Director: Institute for Aging Research at the Albert Einstein College of Medicine Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aging has its own biology that drives age-related diseases, a process that can be targeted.

He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, a professor in the Departments of Medicine and Genetics, the director of the Institute for Aging Research at the Albert Einstein College of Medicine, the Director of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging, and the author of >320 papers.

He is leading an international effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) is a specific study conceived by Dr. Barzilai to prove the concept that a single drug can combat multiple diseases associated with aging and get FDA approval for targeting aging. Dr. Barzilai is a founder and the President of the Academy for Health and Lifespan Research (AHLS).

He is also on the board of directors of the American Federation for Aging Research, where he co-leads its biomarker effort (FAST), TAME, and Super Agers initiative. He is an Executive of the Longevity Biotech Association (LBA) and serves on the council of the Healthy Longevity Medicine Society. He authored Age Later: Health Span, Life Span, and the New Science of Longevity.

Dr. Michael Ringel is Chief Operating Officer at Life Biosciences, a company focused on cellular rejuvenation therapies for diseases of aging. Prior to joining Life Bio, Michael was Managing Director and Senior Partner at BCG, where he worked for 25 years. He is on the Board of Hevolution Foundation US, the charitable organization focused on extending healthy aging for the benefit of all humanity, the Board of AFAR, one of the oldest organizations supporting healthy aging through biomedical research, and on the Executive Board of the Sheba Longevity Center, a clinic devoted to healthy aging at one of the world's best hospitals. Dr. Ringel holds a B.A. summa cum laude in biology from Princeton University, a Ph.D. in biology from Imperial College, and a J.D. cum laude from Harvard Law School.